[go: up one dir, main page]

ZA200904939B - Extended release formulation of nevirapine - Google Patents

Extended release formulation of nevirapine

Info

Publication number
ZA200904939B
ZA200904939B ZA200904939A ZA200904939A ZA200904939B ZA 200904939 B ZA200904939 B ZA 200904939B ZA 200904939 A ZA200904939 A ZA 200904939A ZA 200904939 A ZA200904939 A ZA 200904939A ZA 200904939 B ZA200904939 B ZA 200904939B
Authority
ZA
South Africa
Prior art keywords
nevirapine
release formulation
extended release
formulation
extended
Prior art date
Application number
ZA200904939A
Other languages
English (en)
Inventor
Michael L Cappola
Svetlana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200904939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA200904939B publication Critical patent/ZA200904939B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200904939A 2007-06-08 2009-07-15 Extended release formulation of nevirapine ZA200904939B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
ZA200904939B true ZA200904939B (en) 2010-04-28

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904939A ZA200904939B (en) 2007-06-08 2009-07-15 Extended release formulation of nevirapine

Country Status (28)

Country Link
US (1) US8460704B2 (xx)
EP (1) EP2155169B1 (xx)
JP (1) JP5417662B2 (xx)
KR (1) KR101017862B1 (xx)
CN (1) CN101784263B (xx)
AR (1) AR066924A1 (xx)
AU (1) AU2008262031B2 (xx)
BR (1) BRPI0811732A2 (xx)
CA (1) CA2687491C (xx)
CL (1) CL2008001678A1 (xx)
CO (1) CO6150128A2 (xx)
DK (1) DK2155169T3 (xx)
EA (1) EA018377B1 (xx)
EC (1) ECSP099561A (xx)
ES (1) ES2574836T3 (xx)
HU (1) HUE028598T2 (xx)
IL (1) IL199924A0 (xx)
MA (1) MA31430B1 (xx)
MX (1) MX2009007764A (xx)
NZ (1) NZ578664A (xx)
PE (2) PE20090371A1 (xx)
PL (1) PL2155169T3 (xx)
TN (1) TN2009000510A1 (xx)
TW (1) TWI419716B (xx)
UA (1) UA97971C2 (xx)
UY (1) UY31128A1 (xx)
WO (1) WO2008154234A2 (xx)
ZA (1) ZA200904939B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
NZ578664A (en) 2007-06-08 2011-11-25 Boehringer Ingelheim Int Extended release formulation of nevirapine
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
WO2012164241A1 (en) 2011-05-30 2012-12-06 Cipla Limited Pharmaceutical antiretroviral composition
CN104023784B (zh) * 2011-08-24 2018-05-25 费斯生物制药公司 供持续释放的活性剂制剂
BR112014021927A2 (pt) * 2012-03-05 2019-09-24 Cipla Ltd composição farmacêutica antirretroviral, processo para preparar uma composição farmacêutica antirretroviral, método para o tratamento ou profilaxia de doenças causadas por retrovírus, e, uso de lamivudina, festinavir e nevirapina
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DK1035834T3 (da) * 1997-12-05 2002-07-08 Alza Corp Osmotisk doseringsform omfattende en første og anden coating
JP2002532406A (ja) * 1998-12-17 2002-10-02 アルザ・コーポレーション 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
WO2000059477A1 (en) * 1999-03-31 2000-10-12 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
AU775360B2 (en) * 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
AU2084801A (en) 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
CA2529852A1 (en) 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
DE602004005734T2 (de) 2003-10-01 2007-12-27 Lupin Ltd., Mumbai Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
ES2447816T7 (es) 2003-11-13 2014-06-25 Psivida Us, Inc. Implante inyectable de liberación prolongada que comprende un núcleo de matriz bioerosionable y una piel bioerosionable
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
BRPI0613070A2 (pt) 2005-06-29 2010-12-21 Panacea Biotec Ltd composições farmacêuticas de liberação sustentada e seus processos
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CA2625776A1 (en) * 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
NZ578664A (en) 2007-06-08 2011-11-25 Boehringer Ingelheim Int Extended release formulation of nevirapine

Also Published As

Publication number Publication date
EA200900958A1 (ru) 2010-04-30
EP2155169B1 (en) 2016-03-23
DK2155169T3 (en) 2016-06-13
ES2574836T3 (es) 2016-06-22
KR101017862B1 (ko) 2011-03-04
AR066924A1 (es) 2009-09-23
AU2008262031A1 (en) 2008-12-18
WO2008154234A3 (en) 2010-01-21
AU2008262031B2 (en) 2011-08-25
CA2687491C (en) 2011-09-20
PE20090371A1 (es) 2009-04-24
TW200916127A (en) 2009-04-16
ECSP099561A (es) 2009-09-29
UA97971C2 (ru) 2012-04-10
HK1145806A1 (en) 2011-05-06
IL199924A0 (en) 2010-04-15
EP2155169A2 (en) 2010-02-24
CA2687491A1 (en) 2008-12-18
PE20131035A1 (es) 2013-10-01
JP5417662B2 (ja) 2014-02-19
PL2155169T3 (pl) 2016-09-30
US20100278918A1 (en) 2010-11-04
CN101784263B (zh) 2012-11-07
JP2010520891A (ja) 2010-06-17
CL2008001678A1 (es) 2009-09-11
WO2008154234A9 (en) 2009-11-26
EA018377B1 (ru) 2013-07-30
MX2009007764A (es) 2009-09-10
UY31128A1 (es) 2009-01-30
BRPI0811732A2 (pt) 2014-11-18
KR20100020447A (ko) 2010-02-22
TN2009000510A1 (en) 2011-03-31
TWI419716B (zh) 2013-12-21
MA31430B1 (fr) 2010-06-01
NZ578664A (en) 2011-11-25
CN101784263A (zh) 2010-07-21
US8460704B2 (en) 2013-06-11
WO2008154234A2 (en) 2008-12-18
CO6150128A2 (es) 2010-04-20
HUE028598T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
IL217153A0 (en) Controlled release formulations
PT2345410T (pt) Composição farmacêutica para libertação modificada
IL206791A0 (en) Capsule formulation
ZA201008882B (en) Controlled release of microbiocides
IL201008A0 (en) Modified release dosage forms of tacrolimus
EP2286179A4 (en) Stitching of near-nulled subaperture measurements
ZA200904939B (en) Extended release formulation of nevirapine
GB0720716D0 (en) Novel formulation
IL210149A0 (en) Isolation of cyclopamine
GB0907003D0 (en) Formulation
GB0707463D0 (en) Formulation
GB0822633D0 (en) Formulation
EP2296709A4 (en) NIACIN FORMULATIONS WITH MODIFIED RELEASE
IL208788A (en) Pharmacy-based formulation
ZA201004772B (en) Novel formulation
IL199765A0 (en) Use of tocopherol
EP2285219A4 (en) CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM
EP2291178A4 (en) PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
PH12012501255A1 (en) Sustained release formulation
TWI367205B (en) Preparation of paricalcitol
GB0814376D0 (en) Formulation
ZA201004979B (en) Extracts of sclerocarya birrea
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
GB0911213D0 (en) Formulation
GB0907410D0 (en) Formulation